Review Article
The Molecular Biology of Soft-Tissue Sarcomas and Current Trends in Therapy
Table 7
Current clinical trials with rapalogs in sarcomas.
| | Agent | Human trials | Clinical benefit rate (CR, PR, and SD) | Notes |
| | Temsirolimus | GIST
ASCO 2010 | GIST = 4/15 (27%)
STS = 2/15 (13%) | Refractory GIST | | Temsirolimus | Phase II STS
Mayo Clinic | 5% | | | Sirolimus | Kaposi sarcoma | 15/15 (100%) | Posttransplant KS
Dermal lesions | | Ridaforolimus | Phase II-STS | 61/212 (29%; 2% PR) | IV formulation | | Ridaforolimus | SUCEED trial | PFS: HR = 0.69 () (22.4 versus 14.7 weeks) | Maintenance after ChemoRX |
|
|
